NEOVACS : Half-Year Report on the Liquidity Contract

Regulatory News:

NEOVACS (Paris:ALNEV) (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of June 30, 2013:

• 28,223 shares
• €151,698.16 €

For the prior six month period (December 31, 2012), the corresponding figures were:

• 25,734 shares
• €141,303.51

About NEOVACS
NEOVACS is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. The company’s proprietary technology covered by five patent families that run until at least 2023 has generated to date 2 product candidates in 3 severe diseases: TNF-Kinoid for Rheumatoid Arthritis and Crohn’s Disease and IFNa-Kinoid for Lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr